Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762160 · ClinicalTrials.gov registry record · Phase 2
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Epizyme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04762160 is a Phase 2 study that was terminated before completion, run by Epizyme. The registered enrollment target is 5 participants.
The verdict
NCT04762160, a Phase 2 study, was terminated before completion, sponsored by Epizyme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.
Interventions
- DRUG Tazemetostat
- COMBINATION_PRODUCT Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04762160
The ClinicalTrials.gov registry entry for NCT04762160 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tazemetostat is the first listed.
NCT04762160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04762160 about?
NCT04762160 is a clinical study titled "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma". This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.
What is the current status of trial NCT04762160?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-12-15. Estimated completion is 2022-03-22.
What interventions are being tested in trial NCT04762160?
The interventions under investigation include: Tazemetostat (DRUG), Rituximab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04762160?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.